Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features

PURPOSE: In this multicenter phase II trial, we evaluated atezolizumab combined with bevacizumab in patients with advanced renal cell carcinoma (RCC) with variant histology or any RCC histology with ≥ 20% sarcomatoid differentiation. PATIENTS AND METHODS: Eligible patients may have received previous...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: McGregor, Bradley A., McKay, Rana R., Braun, David A., Werner, Lillian, Gray, Kathryn, Flaifel, Abdallah, Signoretti, Sabina, Hirsch, Michelle S., Steinharter, John A., Bakouny, Ziad, Flippot, Ronan, Wei, Xiao X., Choudhury, Atish, Kilbridge, Kerry, Freeman, Gordon J., Van Allen, Eliezer M., Harshman, Lauren C., McDermott, David F., Vaishampayan, Ulka, Choueiri, Toni K.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2020
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7051851/
https://ncbi.nlm.nih.gov/pubmed/31721643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01882
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky